Carboxamide BRD Inhibitors for Epigenetic Retinal Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ophthalmic diseases such as retinal degeneration, diabetic retinopathy, glaucoma, and macular degeneration are limited by recurrence of diseases, resistance to therapeutic agents, and significant side effects, with no effective therapeutic drugs available for many patients.
Innovation Solution
Development of a novel carboxamide derivative with BRD protein inhibitory activity that inhibits retinal degeneration by suppressing inflammatory responses through epigenetic changes, providing a pharmaceutical composition for preventing and treating these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for ophthalmic diseases are used, then some therapeutic effect is achieved, but disease recurrence and resistance to therapeutic agents occur
Solution Approach 1:
The patent applies parameter changes by developing novel carboxamide derivatives with modified chemical structures (Formula 1 and Formula 2) that exhibit enhanced BRD protein inhibitory activity compared to conventional treatments. The structural modifications including specific substituent groups (R1-R6) and molecular architecture changes enable sustained therapeutic effect and reduced disease recurrence
Solution Approach 2:
The invention employs composite material principles by creating hybrid molecules that combine multiple functional groups (carboxamide, heterocyclic rings, aromatic groups) within a single pharmaceutical compound. This composite structure enables multi-target interaction with BRD proteins while reducing resistance development
2Reliability
If conventional treatments for ophthalmic diseases are used, then some therapeutic effect is achieved, but significant side effects occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific functional groups positioned at particular locations in the molecular structure. The carboxamide group at specific positions and heterocyclic substituents (R1-R6) provide localized interaction with BRD protein binding sites, achieving selective inhibition with reduced off-target effects and minimized side effects
3Reliability
If BRD protein inhibition is achieved through epigenetic changes, then retinal degeneration is inhibited and inflammatory responses are suppressed, but novel compound development is required
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a core carboxamide structure (Formula 1 or Formula 2), heterocyclic ring systems, aromatic groups, and specific substituent patterns (R1-R6). This segmented design allows systematic optimization of BRD inhibition while maintaining manageable structural complexity for pharmaceutical development
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively inhibits retinal degeneration and associated inflammation, offering a potential therapeutic solution for diabetic retinopathy, glaucoma, uveitis, wet and dry macular degeneration, and other ophthalmic diseases, including retinal detachment and choroidal neovascularization, with reduced side effects and improved patient convenience.
Implementation Method 1
JQ1 and other selective BRD inhibitors bind to the BRD protein to prevent acetyl-lysine binding, which prevents BRD proteins from interacting with chromatin, thereby preventing transcription from being regulated
Data Source
Figure 1~3
Figure 4~6
AI summary
The present disclosure relates to a compound of Chemical Formula I or II, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof.